Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
The combination of tusamitamab ravtansine and pembrolizumab with or without chemotherapy generated responses and was well tolerated when used as first-line treatment for patients with CEACAM5-positive nonsquamous nonโsmall cell lung cancer.
Luis Paz Daiichi Sankyo Small Cell Lung Cancer Group Bristol Myers Squibb Oncology Department European Lung Cancer Congress
Source: onclive.com